The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases

ISSN： 1567-2697

Source： Drug Design Reviews - Online, Vol.1, Iss.1, 2004-01, pp. : 53-74

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Toll-like receptors: new therapeutic targets for autoimmune diseases

By O'Neill L.A.J.

Trends in Pharmacological Sciences, Vol. 23, Iss. 6, 2002-06 ,pp. : 257-257

Elsevier

Access to resources Recommend Favorite

Toll-like receptors as therapeutic targets in gastrointestinal diseases

By Pimentel-Nunes Pedro Soares João Bruno Roncon-Albuquerque Jr Roberto Dinis-Ribeiro Mário Leite-Moreira Adelino F

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 4, 2010-04 ,pp. : 347-368

Informa Healthcare

Access to resources Recommend Favorite

Toll-like receptors: emerging targets of immunomodulation

By Quesniaux Valerie FJ Ryffel Bernhard

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 1, 2004-01 ,pp. : 85-100

Informa Healthcare

Access to resources Recommend Favorite

Editorial [Hot Topic: Toll-Like Receptors and Innate Immunity: Potential Drug Targets for Treatment of Infectious, Inflammatory, and Autoimmune Diseases (Executive Editor: Emilio Jirillo)]

Current Pharmaceutical Design, Vol. 12, Iss. 32, 2006-11 ,pp. : 4089-4090

Bentham Science Publishers

Access to resources Recommend Favorite

Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease

Current Pharmaceutical Design, Vol. 24, Iss. 17, 2018-05 ,pp. : 1887-1898

Bentham Science Publishers

Access to resources Recommend Favorite